JP2016516020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516020A5 JP2016516020A5 JP2015562109A JP2015562109A JP2016516020A5 JP 2016516020 A5 JP2016516020 A5 JP 2016516020A5 JP 2015562109 A JP2015562109 A JP 2015562109A JP 2015562109 A JP2015562109 A JP 2015562109A JP 2016516020 A5 JP2016516020 A5 JP 2016516020A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- haloalkyl
- independently selected
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 2
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims 2
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000027004 Eosinophilic disease Diseases 0.000 claims 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000000010 microbial pathogen Species 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13159240.4 | 2013-03-14 | ||
| EP13159240 | 2013-03-14 | ||
| EP13170005.6 | 2013-05-31 | ||
| EP13170005 | 2013-05-31 | ||
| PCT/EP2014/054794 WO2014140075A1 (en) | 2013-03-14 | 2014-03-12 | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017184322A Division JP6689805B2 (ja) | 2013-03-14 | 2017-09-26 | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516020A JP2016516020A (ja) | 2016-06-02 |
| JP2016516020A5 true JP2016516020A5 (cg-RX-API-DMAC10.html) | 2017-09-14 |
| JP6218860B2 JP6218860B2 (ja) | 2017-10-25 |
Family
ID=50272622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562109A Active JP6218860B2 (ja) | 2013-03-14 | 2014-03-12 | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| JP2017184322A Active JP6689805B2 (ja) | 2013-03-14 | 2017-09-26 | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017184322A Active JP6689805B2 (ja) | 2013-03-14 | 2017-09-26 | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
Country Status (27)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026395B (zh) * | 2013-03-14 | 2018-07-20 | 勃林格殷格翰国际有限公司 | 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途 |
| ES2689526T3 (es) | 2013-03-14 | 2018-11-14 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| EP3112366B1 (en) | 2013-03-14 | 2018-02-28 | Janssen Pharmaceutica NV | P2x7 modulators |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| NO2699580T3 (cg-RX-API-DMAC10.html) | 2014-01-24 | 2018-02-24 | ||
| JP2017507983A (ja) | 2014-03-18 | 2017-03-23 | アイティーオス セラペウティクス | 新規な３−インドール置換誘導体、医薬組成物、および使用方法 |
| WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
| US20180118749A1 (en) | 2014-09-12 | 2018-05-03 | Janssen Pharmaceutica Nv | P2x7 modulators |
| EA034015B1 (ru) | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
| NZ728684A (en) | 2014-09-12 | 2022-09-30 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
| UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| EP3265452B1 (en) * | 2015-03-05 | 2020-03-04 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| WO2016139355A1 (en) | 2015-03-05 | 2016-09-09 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| PE20180783A1 (es) | 2015-08-07 | 2018-05-07 | Bayer Cropscience Ag | Derivados heterociclicos condensados sustituidos por 2-(het) arilo como pesticidas |
| UY37137A (es) * | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
| AU2017338824B2 (en) | 2016-10-03 | 2022-01-27 | Sigilon Therapeutics, Inc. | Compounds, devices, and uses thereof |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11690834B2 (en) | 2017-06-23 | 2023-07-04 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Composition, uses, and methods of treating spinal disc degeneration through sonic hedgehog signaling pathway |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
| MA52424B1 (fr) | 2018-03-01 | 2025-04-30 | Astrazeneca Ab | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide |
| WO2019169245A1 (en) | 2018-03-02 | 2019-09-06 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| US12161760B2 (en) | 2018-04-04 | 2024-12-10 | Sigilon Therapeutics, Inc. | Implantable particles and related methods |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| WO2020065613A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| KR20210069079A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| CN110006871A (zh) * | 2019-02-20 | 2019-07-12 | 常州大学 | 一个基于外源性组胺检测的细胞模型以及应用 |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CN114555596B (zh) | 2019-09-30 | 2025-02-25 | 詹森药业有限公司 | 放射性标记的mgl pet配体 |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| AU2021314104A1 (en) | 2020-07-20 | 2023-01-19 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN114159446A (zh) * | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
| WO2022117059A1 (zh) * | 2020-12-04 | 2022-06-09 | 瑞石生物医药有限公司 | 组织蛋白酶c小分子抑制剂及其医药用途 |
| CN116783189B (zh) * | 2021-02-05 | 2026-01-30 | 上海复星医药产业发展有限公司 | 含1，4-氧杂氮杂环庚烷的并环类衍生物 |
| EP4329767A4 (en) * | 2021-04-29 | 2025-03-12 | Insmed Incorporated | CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS |
| CN113831360A (zh) * | 2021-09-10 | 2021-12-24 | 中钢集团南京新材料研究院有限公司 | 酰胺邻位导向硼化合成1-咔唑-硼酸频哪醇酯的方法 |
| CN116462677A (zh) * | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| US20230234973A1 (en) * | 2022-01-27 | 2023-07-27 | Heron Neutron Medical Corp. | Intermediate, preparing method thereof, and method of preparing drug |
| CN114773345B (zh) * | 2022-03-22 | 2024-01-02 | 盐城工业职业技术学院 | 一种哌嗪二酮衍生物及其制备方法 |
| WO2023208081A1 (en) * | 2022-04-28 | 2023-11-02 | Shenzhen Bay Laboratory | Substituted fluorosulfate and use thereof |
| CA3257803A1 (en) | 2022-06-13 | 2025-04-04 | Alivexis, Inc. | AZACYCLOLAKYL CARBONYL CYCLIC AMINE COMPOUND |
| KR20250120411A (ko) | 2022-12-16 | 2025-08-08 | 신젠타 크롭 프로텍션 아게 | 벤즈이미다졸 유도체 |
| CN115974824B (zh) * | 2022-12-27 | 2024-09-24 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| AU2024206233A1 (en) | 2023-01-06 | 2025-08-21 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025167969A1 (en) * | 2024-02-07 | 2025-08-14 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
| WO2025214073A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| GB8922355D0 (en) | 1989-10-04 | 1989-11-22 | British Telecomm | Sealing gland |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| DE20012487U1 (de) | 2000-07-19 | 2001-04-05 | Wenger, Lukas, 85521 Ottobrunn | Beheizbare Scheibenwischer an Kraftfahrzeugen |
| ATE409482T1 (de) | 2001-03-02 | 2008-10-15 | Merck Frosst Canada Ltd | Cathepsincystein-proteasehemmer |
| US6982263B2 (en) * | 2001-06-08 | 2006-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitriles useful as reversible inhibitors of cysteine proteases |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| EP1638925A1 (en) | 2003-06-18 | 2006-03-29 | Prozymex A/S | Protease inhibitors |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| CN1921907A (zh) * | 2004-01-08 | 2007-02-28 | 默克弗罗斯特加拿大有限公司 | 组织蛋白酶半胱氨酸蛋白酶抑制剂 |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2009047829A1 (ja) * | 2007-10-12 | 2009-04-16 | Fujitsu Limited | Ｉｐ電話自動試験システム及び方法 |
| CA2706679A1 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Novel compounds 010 |
| KR20120034639A (ko) | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2012119941A1 (en) * | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| UY34765A (es) | 2012-04-27 | 2013-11-29 | Glaxo Group Ltd | Compuestos novedosos. |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9914730B2 (en) | 2012-09-28 | 2018-03-13 | Cancer Research Technology Limited | Azaquinazoline inhibitors of Atypical protein Kinase C |
| JP2015533134A (ja) | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用 |
| US9006242B2 (en) | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
| SG11201502369XA (en) | 2012-10-16 | 2015-05-28 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
| SG11201503141TA (en) | 2012-11-01 | 2015-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| WO2014100620A2 (en) | 2012-12-21 | 2014-06-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| CN105026372B (zh) | 2012-12-21 | 2018-06-05 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| CA2900012A1 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| CN105026395B (zh) | 2013-03-14 | 2018-07-20 | 勃林格殷格翰国际有限公司 | 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途 |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| AU2014241079C1 (en) | 2013-03-14 | 2017-07-06 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| EP3164272A1 (en) | 2014-07-03 | 2017-05-10 | Bridgestone Americas Tire Operations, LLC | Sidewall decoration on rim guard |
| SMT201900019T1 (it) | 2014-09-12 | 2019-02-28 | Glaxosmithkline Ip No 2 Ltd | Derivati di tetraidrochinolina come inibitori di bromodominio |
| TW201625591A (zh) | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2014
- 2014-03-12 CN CN201480013346.3A patent/CN105026395B/zh active Active
- 2014-03-12 DK DK14709652.3T patent/DK2970283T3/da active
- 2014-03-12 EP EP14709652.3A patent/EP2970283B1/en active Active
- 2014-03-12 WO PCT/EP2014/054794 patent/WO2014140075A1/en not_active Ceased
- 2014-03-12 AP AP2015008601A patent/AP2015008601A0/xx unknown
- 2014-03-12 ES ES14709652T patent/ES2845473T3/es active Active
- 2014-03-12 PL PL14709652T patent/PL2970283T3/pl unknown
- 2014-03-12 TW TW103108810A patent/TW201522307A/zh unknown
- 2014-03-12 KR KR1020157025088A patent/KR102295740B1/ko active Active
- 2014-03-12 MX MX2015011799A patent/MX363936B/es active IP Right Grant
- 2014-03-12 CA CA2903569A patent/CA2903569C/en active Active
- 2014-03-12 JP JP2015562109A patent/JP6218860B2/ja active Active
- 2014-03-12 US US14/205,861 patent/US8987249B2/en active Active
- 2014-03-12 AU AU2014230814A patent/AU2014230814B2/en active Active
- 2014-03-12 UY UY35391A patent/UY35391A/es unknown
- 2014-03-12 PE PE2015001928A patent/PE20151727A1/es not_active Application Discontinuation
- 2014-03-12 SG SG11201507382QA patent/SG11201507382QA/en unknown
- 2014-03-12 HU HUE14709652A patent/HUE053431T2/hu unknown
- 2014-03-12 HK HK15112308.5A patent/HK1211579A1/xx unknown
- 2014-03-12 NZ NZ710034A patent/NZ710034A/en unknown
- 2014-03-12 GE GEAP201413959A patent/GEP201706780B/en unknown
- 2014-03-12 BR BR112015019720A patent/BR112015019720B8/pt active IP Right Grant
- 2014-03-12 CN CN201810715894.0A patent/CN108707140B/zh active Active
- 2014-03-12 EA EA201500923A patent/EA029052B1/ru not_active IP Right Cessation
- 2014-12-18 US US14/574,573 patent/US20150105375A1/en not_active Abandoned
-
2015
- 2015-07-20 IL IL240030A patent/IL240030B/en active IP Right Grant
- 2015-08-17 CL CL2015002301A patent/CL2015002301A1/es unknown
- 2015-08-31 TN TN2015000381A patent/TN2015000381A1/en unknown
- 2015-09-04 PH PH12015501964A patent/PH12015501964B1/en unknown
- 2015-12-01 US US14/955,379 patent/US9713606B2/en active Active
-
2017
- 2017-06-06 US US15/614,996 patent/US10238633B2/en active Active
- 2017-09-26 JP JP2017184322A patent/JP6689805B2/ja active Active
-
2019
- 2019-02-08 US US16/271,068 patent/US20190167636A1/en not_active Abandoned
- 2019-12-19 US US16/720,347 patent/US20200138780A1/en not_active Abandoned
-
2021
- 2021-04-19 US US17/234,004 patent/US20210260027A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,492 patent/US20230310373A1/en not_active Abandoned